October 31, 2013
RESEARCH TRIANGLE PARK, N.C. — Humacyte, Inc., a pioneer in regenerative medicine, today announced that it has received the 2013 North Carolina Excellence Award from the Small Business Institute for Excellence in Commerce (SBIEC) for its continued advancement of business leadership and high regard for upholding business ethics and company values among its peers.
“Strengthening our position within the North Carolina business community is consistent with our company philosophy of growing our leadership position in vascular tissue engineering with medical applications that target high unmet medical needs of physicians and patients,” said Dr. Ted Lithgow, chief operating officer, Humacyte. “Our innovative technology has created the first investigational bioengineered blood vessels that are being developed to be stored “off-the-shelf” for future use in hemodialysis applications, pending regulatory approval.”
Each year, the SBIEC surveys the local business community and industry research reports to identify companies that have achieved demonstrable success in their local business environment and industry category. Companies who are selected for this award are recognized for having enhanced the commitment and contribution of small businesses through service to their customers and community. This recognition of Humacyte by SBIEC marks a significant achievement as an emerging leader within various competitors and sets a benchmark that the overall industry should follow.
Humacyte, Inc., a privately held company founded in 2005, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative and proprietary platform technology to engineer human, extracellular matrix-based tissues designed to be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for a variety of patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to result in off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.
The SBIEC is a leading authority on researching, evaluating and recognizing companies across a wide spectrum of industries that meet its stringent standards of excellence. It has spearheaded the idea of independent enterprise and entrepreneurial growth allowing businesses of all sizes to be recognized. More information on SBIEC can be found at www.sbiec.org